GlassScriptPhysician profile
Leon J Khoury
NPI 1467498014
$2,541.24
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,312 · 2020: $309 · 2021: $97.94 · 2022: $822.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $743.41 | 2019-2022 | |
| Amgen INC. | $324.46 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $299.56 | 2019-2022 | |
| Pfizer INC. | $263.00 | 2019-2022 | |
| Abbott Laboratories | $243.37 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $115.62 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $115.36 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $93.63 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $81.85 | 2019-2020 | |
| Amarin Pharma, INC. | $57.16 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $53.05 | 2021-2022 | |
| Boston Scientific Corporation | $48.81 | 2019-2022 | |
| Daiichi Sankyo INC. | $37.82 | 2019-2022 | |
| Astellas Pharma US INC | $21.05 | 2020 | |
| Akcea Therapeutics, INC. | $20.32 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.47 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $11.30 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leon Khoury listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.